Suchen
Pharvaris NV
PHVSZur Watchlist hinzufügen
33.070USD
-2.130-6.05%
Handelsschluss 09-23 16:00（ET）
2.30BMarktkapitalisierung
VerlustKGV TTM
Über Pharvaris NV Unternehmen
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NV Profil
BörsenkürzelPHVS
Name des UnternehmensPharvaris NV
IPO-datumFeb 05, 2021
CEOModig (Berndt B.A.E)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 05
AddresseEmmy Noetherweg 2
StadtLEIDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl2333 BK
Telefon31712036410
Websitehttps://pharvaris.com/
BörsenkürzelPHVS
IPO-datumFeb 05, 2021
CEOModig (Berndt B.A.E)
Führungskräfte von Pharvaris NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Pharvaris NV?
Die fünf größten Anteilseigner von Pharvaris NV sind: Dr. Peng Lu, M.D., Ph.D.
Wie viele Institutionen halten Anteile an Pharvaris NV (PHVS)?
Mit Stand vom 2026Q1 halten 165 Institutionen Anteile an Pharvaris NV, mit einem Gesamtmarktwert von etwa 59.26M, was 90.60% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -451327.00 gestiegen.